01- Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis
Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement.
Read more HERE
02- Major Cause of Myocardial Injury by COVID-19
The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These microthrombi resulted quite different in composition vs. thrombi obtained from COVID-19 negative patients and thrombi obtained from infected patients with ACS.
Read more HERE
03- Contralateral Occluded Carotid Defines Revascularization Strategy
A significative lesion to the carotid artery in addition to contralateral carotid occlusion is an obvious factor of high risk for a revascularization procedure. However, this might be true for surgery but not for carotid artery stenting according to this recent publication in JACC.
Read more HERE
04- Improvements in COAPT Trial for Functional Mitral Regurgitation
Patients with heart failure and moderate-to-severe secondary mitral regurgitation may benefit from transcatheter mitral valve repair. There are benefits at 3 years, even in hard points such as mortality rate.
Read more HERE
05- Solution for Type 1A Endoleaks After Abdominal Endoprosthesis
Proximal type 1 endoleaks after endovascular abdominal aortic aneurysmal repair are challenging to solve, with no existing consensus on the proper solution.
Read more HERE
06- You Are Invited to The Fellow’s Corner 2021
After a long vacation, we are back on track and fully recharged to continue with a ProEducar-SOLACI project called The Fellow’s Corner.
Read more HERE
07- The Most Read Articles in Interventional Cardiology during February
These were the most read scientific articles of February in interventional cardiology on our website. Don’t miss out.
Read more HERE
08- Watch again our Webinar on Left Main PCI and Bifurcations: LATAM Bif Registry
Watch again our Webinar on “Left Main PCI and Bifurcations: LATAM Bif Registry” on our Youtube account. The event was held on March 3rd, 2021, and had the participation of almost 700 people and the support of ABBOTT, Boston Scientific, Medtronic and Terumo.
Read more HERE
09- TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.
At two-year followup, primary end point continued to be significantly lower with Sapien 3 vs. conventional surgery, but the initial difference in death and stroke in favor of TAVR started to shrink. In addition, there was higher risk of valve thrombosis in TAVR patients.
Read more HERE
10- Biodegradable Polymer Myth Also Debunked for ACSs
During TCT 2020 a preview of the results of the comparison of drug-eluting stents (DES) with biodegradable-polymer vs. durable-polymer in patients with acute coronary syndrome (ACS) was presented. The fine print and the final paper for HOST-REDUCE-POLYTECH-ACS are now published, and they lower the expectations set on biodegradable polymers.
Read more HERE
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
